261 related articles for article (PubMed ID: 37076815)
1. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway.
Chen X; Lu T; Cai Y; Han Y; Ding M; Chu Y; Zhou X; Wang X
Cell Mol Biol Lett; 2023 Apr; 28(1):32. PubMed ID: 37076815
[TBL] [Abstract][Full Text] [Related]
2. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
4. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
[TBL] [Abstract][Full Text] [Related]
5. Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism.
Chen X; Lu T; Ding M; Cai Y; Yu Z; Zhou X; Wang X
J Adv Res; 2023 Oct; ():. PubMed ID: 37865189
[TBL] [Abstract][Full Text] [Related]
6. KIAA1429 facilitates metastasis via m6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells.
Shan M; Liu D; Sun L; Yang M; He M; Zhang Y; Xiang L; Lu L; He H; Niu D; Chen L; Li S; Chen A; He F; Wang Y; Lian J
Cancer Lett; 2024 Mar; 584():216598. PubMed ID: 38224863
[TBL] [Abstract][Full Text] [Related]
7. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
[TBL] [Abstract][Full Text] [Related]
8. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
Han H; Fan G; Song S; Jiang Y; Qian C; Zhang W; Su Q; Xue X; Zhuang W; Li B
Blood; 2021 Mar; 137(12):1603-1614. PubMed ID: 32967010
[TBL] [Abstract][Full Text] [Related]
9. KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer.
Miao R; Dai CC; Mei L; Xu J; Sun SW; Xing YL; Wu LS; Wang MH; Wei JF
J Cell Physiol; 2020 Oct; 235(10):7420-7432. PubMed ID: 32052427
[TBL] [Abstract][Full Text] [Related]
10. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA.
Cheng X; Li M; Rao X; Zhang W; Li X; Wang L; Huang G
Onco Targets Ther; 2019; 12():3421-3428. PubMed ID: 31118692
[TBL] [Abstract][Full Text] [Related]
11. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
Zhao W; Xie Y
Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
[TBL] [Abstract][Full Text] [Related]
12. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.
Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G
J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593
[TBL] [Abstract][Full Text] [Related]
13. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
14. METTL3 enhances the effect of YTHDF1 on NEDD1 mRNA stability by m6A modification in diffuse large B-cell lymphoma cells.
Feng L; Yan Q; Pan H; Shi W
Immun Inflamm Dis; 2023 Feb; 11(2):e789. PubMed ID: 36840486
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma.
Tan K; Lu W; Chen F; Shi H; Ma Y; Chen Z; Wu W; Lv Z; Mo J
J Exp Clin Cancer Res; 2023 Sep; 42(1):250. PubMed ID: 37759224
[TBL] [Abstract][Full Text] [Related]
16. VIRMA contributes to non-small cell lung cancer progression via N
Xu Y; Chen Y; Yao Y; Xie H; Lu G; Du C; Cheng J; Zhou J
Cancer Lett; 2021 Dec; 522():142-154. PubMed ID: 34520821
[TBL] [Abstract][Full Text] [Related]
17. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
18. KIAA1429 Promotes Nasopharyngeal Carcinoma Progression by Mediating m6A Modification of PTGS2.
Wu L; Zhou Y; Fu J
Crit Rev Immunol; 2023; 43(4):15-27. PubMed ID: 37830191
[TBL] [Abstract][Full Text] [Related]
19. KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner.
Ma L; Lin Y; Sun SW; Xu J; Yu T; Chen WL; Zhang LH; Guo YC; Wang YW; Chen T; Wei JF; Zhu LJ
Oncogene; 2022 Jan; 41(5):692-703. PubMed ID: 34819634
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
